Reviews
Description
Part I: Basics and Introduction
1. Invention and Early History
Kenji Rowel Q. Lim and Toshifumi Yokota
2. Development and Clinical Applications of Antisense Oligonucleotide Gapmers
Leanna Chan and Toshifumi Yokota
3. Knocking Down Long Non-coding RNAs using Antisense Oligonucleotide Gapmers
Rika Maruyama and Toshifumi Yokota
4. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease
Tejal Aslesh and Toshifumi Yokota
5. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Tejal Aslesh and Toshifumi Yokota
6. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis
Maria Mahfouz, Rika Maruyama, and Toshifumi Yokota
7. Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides
Quynh Nguyen and Toshifumi Yokota
Part II: Design of Gapmers and Strategy
8. DNA/RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing
Rintaro Iwata Hara, Kotaro Yoshioka, and Takanori Yokota
9. Tips for Successful lncRNA Knockdown using Gapmers
Kim A Lennox and Mark A Behlke
10. Calcium-Mediated In Vitro Transfection Technique of Oligonucleotides with Broad Chemical Modification Compatibility
Fumito Wada, Shin-ichiro Hori, Satoshi Obika, and Tsuyoshi Yamamoto
11. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers in vitro
Shinzo Iwashita, Takao Shoji, and Makoto Koizumi
12. Albumin-binding Fatty Acid-modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics
Yunpeng Cai, Chenguang Lou, Jesper Wengel, and Kenneth A. Howard
Part III: In Vitro/In Vivo Evaluation of Gapmers and Antisense Oligonucleotides
13. The use of Gapmers for in vivo Suppression of Hepatic mRNA Targets
David S. Greenberg, Yonat Tzur, and Hermona Soreq
14. Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/ FTD Caused by the C9orf72 Repeat Expansion
Chaitra Sathyaprakash, Raquel Manzano, Miguel A. Varela, Yasumasa Hashimoto, Matthew J. A. Wood, Kevin Talbot, and Yoshitsugu Aoki
15. Targeted Gene Silencing in Malignant Hematolymphoid Cells using GapmeR
Atish Kizhakeyil, Mobashar Hussain Urf Turabe Fazil, and Navin Kumar Verma
16. Gapmer Antisense Oligonucleotides to Selectively Suppress the Mutant allele in COL6A Genes in Sominant Ullrich Congenital Muscular Dystrophy
Sara Aguti, Elena Marrosu, Francesco Muntoni, and Haiyan Zhou
Part IV: Detection of Gapmers
17. Detection of Locked Nucleic Acid Gapmers from Mouse Samples using ELISA
Kenji Rowel Q. Lim, Quynh Nguyen, and Toshifumi Yokota
EXTRA 10 % discount with code: EXTRA
The promotion ends in 18d.09:07:42
The discount code is valid when purchasing from 10 €. Discounts do not stack.
Part I: Basics and Introduction
1. Invention and Early History
Kenji Rowel Q. Lim and Toshifumi Yokota
2. Development and Clinical Applications of Antisense Oligonucleotide Gapmers
Leanna Chan and Toshifumi Yokota
3. Knocking Down Long Non-coding RNAs using Antisense Oligonucleotide Gapmers
Rika Maruyama and Toshifumi Yokota
4. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease
Tejal Aslesh and Toshifumi Yokota
5. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Tejal Aslesh and Toshifumi Yokota
6. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis
Maria Mahfouz, Rika Maruyama, and Toshifumi Yokota
7. Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides
Quynh Nguyen and Toshifumi Yokota
Part II: Design of Gapmers and Strategy
8. DNA/RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing
Rintaro Iwata Hara, Kotaro Yoshioka, and Takanori Yokota
9. Tips for Successful lncRNA Knockdown using Gapmers
Kim A Lennox and Mark A Behlke
10. Calcium-Mediated In Vitro Transfection Technique of Oligonucleotides with Broad Chemical Modification Compatibility
Fumito Wada, Shin-ichiro Hori, Satoshi Obika, and Tsuyoshi Yamamoto
11. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers in vitro
Shinzo Iwashita, Takao Shoji, and Makoto Koizumi
12. Albumin-binding Fatty Acid-modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics
Yunpeng Cai, Chenguang Lou, Jesper Wengel, and Kenneth A. Howard
Part III: In Vitro/In Vivo Evaluation of Gapmers and Antisense Oligonucleotides
13. The use of Gapmers for in vivo Suppression of Hepatic mRNA Targets
David S. Greenberg, Yonat Tzur, and Hermona Soreq
14. Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/ FTD Caused by the C9orf72 Repeat Expansion
Chaitra Sathyaprakash, Raquel Manzano, Miguel A. Varela, Yasumasa Hashimoto, Matthew J. A. Wood, Kevin Talbot, and Yoshitsugu Aoki
15. Targeted Gene Silencing in Malignant Hematolymphoid Cells using GapmeR
Atish Kizhakeyil, Mobashar Hussain Urf Turabe Fazil, and Navin Kumar Verma
16. Gapmer Antisense Oligonucleotides to Selectively Suppress the Mutant allele in COL6A Genes in Sominant Ullrich Congenital Muscular Dystrophy
Sara Aguti, Elena Marrosu, Francesco Muntoni, and Haiyan Zhou
Part IV: Detection of Gapmers
17. Detection of Locked Nucleic Acid Gapmers from Mouse Samples using ELISA
Kenji Rowel Q. Lim, Quynh Nguyen, and Toshifumi Yokota
Reviews